Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
MMWR Morb Mortal Wkly Rep ; 72(49): 1315-1320, 2023 Dec 08.
Article in English | MEDLINE | ID: mdl-38060434

ABSTRACT

Legionnaires disease is a serious infection acquired by inhalation of water droplets from human-made building water systems that contain Legionella bacteria. On July 11 and 12, 2022, Napa County Public Health (NCPH) in California received reports of three positive urinary antigen tests for Legionella pneumophila serogroup 1 in the town of Napa. By July 21, six Legionnaires disease cases had been confirmed among Napa County residents, compared with a baseline of one or two cases per year. NCPH requested assistance from the California Department of Public Health (CDPH) and CDC to aid in the investigations. Close temporal and geospatial clustering permitted a focused environmental sampling strategy of high-risk facilities which, coupled with whole genome sequencing results from samples and investigation of water system maintenance, facilitated potential linking of the outbreak with an environmental source. NCPH, with technical support from CDC and CDPH, instructed and monitored remediation practices for all environmental locations that tested positive for Legionella. The investigation response to this community outbreak illustrates the importance of interdisciplinary collaboration by public health agencies, laboratory support, timely communication with the public, and cooperation of managers of potentially implicated water systems. Timely identification of possible sources, sampling, and remediation of any facility testing positive for Legionella is crucial to interrupting further transmission.


Subject(s)
Legionella pneumophila , Legionella , Legionnaires' Disease , Humans , Legionnaires' Disease/diagnosis , Legionnaires' Disease/epidemiology , Disease Outbreaks , Water Microbiology , California/epidemiology , Water
3.
Eur J Med Chem ; 242: 114698, 2022 Nov 15.
Article in English | MEDLINE | ID: mdl-36037791

ABSTRACT

A clinically significant mechanism of tuberculosis resistance to the aminoglycoside kanamycin (KAN) is its acetylation catalyzed by upregulated Mycobacterium tuberculosis (Mtb) acetyltransferase Eis. In search for inhibitors of Eis, we discovered an inhibitor with a substituted benzyloxy-benzylamine scaffold. A structure-activity relationship study of 38 compounds in this structural family yielded highly potent (IC50 ∼ 1 µM) Eis inhibitors, which did not inhibit other acetyltransferases. Crystal structures of Eis in complexes with three of the inhibitors showed that the inhibitors were bound in the aminoglycoside binding site of Eis, consistent with the competitive mode of inhibition, as established by kinetics measurements. When tested in Mtb cultures, two inhibitors (47 and 55) completely abolished resistance to KAN of the highly KAN-resistant strain Mtb mc2 6230 K204, likely due to Eis inhibition as a major mechanism. Thirteen of the compounds were toxic even in the absence of KAN to Mtb and other mycobacteria, but not to non-mycobacteria or to mammalian cells. This, yet unidentified mechanism of toxicity, distinct from Eis inhibition, will merit future studies along with further development of these molecules as anti-mycobacterial agents.


Subject(s)
Acetyltransferases , Mycobacterium tuberculosis , Acetyltransferases/chemistry , Aminoglycosides/pharmacology , Animals , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Antitubercular Agents/chemistry , Bacterial Proteins , Benzylamines/pharmacology , Kanamycin/chemistry , Kanamycin/pharmacology , Mammals/metabolism , Mycobacterium tuberculosis/metabolism
4.
RSC Med Chem ; 12(11): 1894-1909, 2021 Nov 17.
Article in English | MEDLINE | ID: mdl-34825186

ABSTRACT

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly bacterial disease. Drug-resistant strains of Mtb make eradication of TB a daunting task. Overexpression of the enhanced intracellular survival (Eis) protein by Mtb confers resistance to the second-line antibiotic kanamycin (KAN). Eis is an acetyltransferase that acetylates KAN, inactivating its antimicrobial function. Development of Eis inhibitors as KAN adjuvant therapeutics is an attractive path to forestall and overcome KAN resistance. We discovered that an antipsychotic drug, haloperidol (HPD, 1), was a potent Eis inhibitor with IC50 = 0.39 ± 0.08 µM. We determined the crystal structure of the Eis-haloperidol (1) complex, which guided synthesis of 34 analogues. The structure-activity relationship study showed that in addition to haloperidol (1), eight analogues, some of which were smaller than 1, potently inhibited Eis (IC50 ≤ 1 µM). Crystal structures of Eis in complexes with three potent analogues and droperidol (DPD), an antiemetic and antipsychotic, were determined. Three compounds partially restored KAN sensitivity of a KAN-resistant Mtb strain K204 overexpressing Eis. The Eis inhibitors generally did not exhibit cytotoxicity against mammalian cells. All tested compounds were modestly metabolically stable in human liver microsomes, exhibiting 30-60% metabolism over the course of the assay. While direct repurposing of haloperidol as an anti-TB agent is unlikely due to its neurotoxicity, this study reveals potential approaches to modifying this chemical scaffold to minimize toxicity and improve metabolic stability, while preserving potent Eis inhibition.

5.
Article in English | MEDLINE | ID: mdl-33106264

ABSTRACT

Fluoroquinolones (FQ) are crucial components of multidrug-resistant tuberculosis (MDR TB) treatment. Differing levels of resistance are associated with specific mutations within the quinolone-resistance-determining region (QRDR) of gyrA We sequenced the QRDR from serial isolates of MDR TB patients in the Preserving Effective TB Treatment Study (PETTS) with baseline FQ resistance (FQR) or acquired FQ resistance (FQACQR) using an Ion Torrent Personal Genome Machine (PGM) to a depth of 10,000× and reported single nucleotide polymorphisms in ≥1% of reads. FQR isolates harbored 15 distinct alleles with 1.3 (maximum = 6) on average per isolate. Eighteen alleles were identified in FQACQR isolates with an average of 1.6 (maximum = 9) per isolate. Isolates from 78% of FQACQR individuals had mutant alleles identified within 6 months of treatment initiation. Asp94Gly was the predominant allele in the initial FQ-resistant isolates followed by Ala90Val. Seventy-seven percent (36/47) of FQACQR group patients had isolates with FQ resistance alleles prior to changes to the FQ component of their treatment. Unlike the individuals treated initially with other FQs, none of the 21 individuals treated initially with levofloxacin developed genotypic or phenotypic FQ resistance, although country of residence was likely a contributing factor since 69% of these individuals were from a single country. Initial detection of phenotypic resistance and genotypic resistance occurred simultaneously for most; however, phenotypic resistance occurred earlier in isolates harboring mixtures of alleles of very low abundance (<1% of reads), whereas genotypic resistance often occurred earlier for alleles associated with low-level resistance. Understanding factors influencing acquisition and evolution of FQ resistance could reveal strategies for improved treatment success.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis, Multidrug-Resistant , Antitubercular Agents/pharmacology , DNA Gyrase/genetics , Drug Resistance, Multiple, Bacterial/genetics , Fluoroquinolones/pharmacology , Humans , Microbial Sensitivity Tests , Mycobacterium tuberculosis/genetics , Tuberculosis, Multidrug-Resistant/drug therapy
6.
ACS Chem Biol ; 15(6): 1581-1594, 2020 06 19.
Article in English | MEDLINE | ID: mdl-32421305

ABSTRACT

The enhanced intracellular survival (Eis) protein of Mycobacterium tuberculosis (Mtb) is a versatile acetyltransferase that multiacetylates aminoglycoside antibiotics abolishing their binding to the bacterial ribosome. When overexpressed as a result of promoter mutations, Eis causes drug resistance. In an attempt to overcome the Eis-mediated kanamycin resistance of Mtb, we designed and optimized structurally unique thieno[2,3-d]pyrimidine Eis inhibitors toward effective kanamycin adjuvant combination therapy. We obtained 12 crystal structures of enzyme-inhibitor complexes, which guided our rational structure-based design of 72 thieno[2,3-d]pyrimidine analogues divided into three families. We evaluated the potency of these inhibitors in vitro as well as their ability to restore the activity of kanamycin in a resistant strain of Mtb, in which Eis was upregulated. Furthermore, we evaluated the metabolic stability of 11 compounds in vitro. This study showcases how structural information can guide Eis inhibitor design.


Subject(s)
Acetyltransferases/antagonists & inhibitors , Bacterial Proteins/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Mycobacterium tuberculosis/enzymology , Drug Design , Kanamycin Resistance/drug effects , Microbial Sensitivity Tests , Models, Molecular , Molecular Structure , Mycobacterium tuberculosis/drug effects , Structure-Activity Relationship
7.
ACS Infect Dis ; 4(6): 1030-1040, 2018 06 08.
Article in English | MEDLINE | ID: mdl-29601176

ABSTRACT

A common cause of resistance to kanamycin (KAN) in tuberculosis is overexpression of the enhanced intracellular survival (Eis) protein. Eis is an acetyltransferase that multiacetylates KAN and other aminoglycosides, rendering them unable to bind the bacterial ribosome. By high-throughput screening, a series of substituted 1,2,4-triazino[5,6 b]indole-3-thioether molecules were identified as effective Eis inhibitors. Herein, we purchased 17 and synthesized 22 new compounds, evaluated their potency, and characterized their steady-state kinetics. Four inhibitors were found not only to inhibit Eis in vitro, but also to act as adjuvants of KAN and partially restore KAN sensitivity in a Mycobacterium tuberculosis KAN-resistant strain in which Eis is upregulated. A crystal structure of Eis in complex with a potent inhibitor and CoA shows that the inhibitors bind in the aminoglycoside binding site snugly inserted into a hydrophobic cavity. These inhibitors will undergo preclinical development as novel KAN adjuvant therapies to treat KAN-resistant tuberculosis.


Subject(s)
Acetyltransferases/antagonists & inhibitors , Acetyltransferases/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Indoles/chemistry , Indoles/pharmacology , Kanamycin Resistance/drug effects , Mycobacterium tuberculosis/enzymology , A549 Cells , Acetyltransferases/metabolism , Antitubercular Agents/pharmacology , Bacterial Proteins/metabolism , Binding Sites , HEK293 Cells , Humans , Indoles/chemical synthesis , Kanamycin/pharmacology , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Protein Binding , Protein Structure, Secondary , Regression Analysis , Sulfides/chemistry , Triazines/chemistry
8.
Biochemistry ; 57(5): 781-790, 2018 02 06.
Article in English | MEDLINE | ID: mdl-29345920

ABSTRACT

Bacterial nucleoid-associated proteins (NAPs) are critical to genome integrity and chromosome maintenance. Post-translational modifications of bacterial NAPs appear to function similarly to their better studied mammalian counterparts. The histone-like NAP HupB from Mycobacterium tuberculosis (Mtb) was previously observed to be acetylated by the acetyltransferase Eis, leading to genome reorganization. We report biochemical and structural aspects of acetylation of HupB by Eis. We also found that the SirT-family NAD+-dependent deacetylase Rv1151c from Mtb deacetylated HupB in vitro and characterized the deacetylation kinetics. We propose that activities of Eis and Rv1151c could regulate the acetylation status of HupB to remodel the mycobacterial chromosome in response to environmental changes.


Subject(s)
Acetyltransferases/metabolism , Bacterial Proteins/metabolism , Histone Deacetylases/metabolism , Histones/metabolism , Mycobacterium tuberculosis/metabolism , Acetylation , Acetyltransferases/antagonists & inhibitors , Acetyltransferases/genetics , Amino Acid Sequence , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/genetics , Cloning, Molecular , Crystallography, X-Ray , Drug Resistance, Multiple, Bacterial/genetics , Gene Expression Regulation, Bacterial/drug effects , Gene Expression Regulation, Bacterial/physiology , Histone Deacetylases/genetics , Histones/genetics , Kinetics , Lysine/chemistry , Models, Molecular , Mycobacterium tuberculosis/genetics , Peptide Fragments/metabolism , Protein Conformation , Protein Interaction Mapping , Protein Processing, Post-Translational , Recombinant Proteins/metabolism , Sequence Alignment , Sequence Homology, Amino Acid , Tandem Mass Spectrometry
9.
Article in English | MEDLINE | ID: mdl-29084743

ABSTRACT

Pyrazinamide (PZA) is a standard component of first-line treatment regimens for Mycobacterium tuberculosis and is included in treatment regimens for drug-resistant M. tuberculosis whenever possible. Therefore, it is imperative that susceptibility to PZA be assessed reliably prior to the initiation of therapy. Currently available growth-based PZA susceptibility tests are time-consuming, and results can be inconsistent. Molecular tests have been developed for most first-line antituberculosis drugs; however, a commercial molecular test is not yet available for rapid detection of PZA resistance. Recently, a line probe assay, the Nipro Genoscholar PZA-TB II assay, was developed for the detection of mutations within the pncA gene, including the promoter region, that are likely to lead to PZA resistance. The sensitivity and specificity of this assay were evaluated by two independent laboratories, using a combined total of 249 strains with mutations in pncA or its promoter and 21 strains with wild-type pncA Overall, the assay showed good sensitivity (93.2% [95% confidence interval, 89.3 to 95.8%]) and moderate specificity (91.2% [95% confidence interval, 77.0 to 97.0%]) for the identification of M. tuberculosis strains predicted to be resistant to PZA on the basis of the presence of mutations (excluding known PZA-susceptible mutations) in the pncA coding region or promoter. The assay shows promise for the molecular prediction of PZA resistance.


Subject(s)
Bacterial Proteins/genetics , Biological Assay/methods , Mutation/genetics , Mycobacterium tuberculosis/genetics , Antitubercular Agents/pharmacology , Drug Resistance, Bacterial/genetics , Humans , Microbial Sensitivity Tests/methods , Mycobacterium tuberculosis/drug effects , Promoter Regions, Genetic/genetics , Pyrazinamide/pharmacology , Tuberculosis, Multidrug-Resistant
10.
ACS Infect Dis ; 3(4): 302-309, 2017 04 14.
Article in English | MEDLINE | ID: mdl-28192916

ABSTRACT

Tuberculosis (TB) remains one of the leading causes of mortality worldwide. Hence, the identification of highly effective antitubercular drugs with novel modes of action is crucial. In this paper, we report the discovery and development of pyrrolo[1,5-a]pyrazine-based analogues as highly potent inhibitors of the Mycobacterium tuberculosis (Mtb) acetyltransferase enhanced intracellular survival (Eis), whose up-regulation causes clinically observed resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN). We performed a structure-activity relationship (SAR) study to optimize these compounds as potent Eis inhibitors both against purified enzyme and in mycobacterial cells. A crystal structure of Eis in complex with one of the most potent inhibitors reveals that the compound is bound to Eis in the AG binding pocket, serving as the structural basis for the SAR. These Eis inhibitors have no observed cytotoxicity to mammalian cells and are promising leads for the development of innovative AG adjuvant therapies against drug-resistant TB.


Subject(s)
Antitubercular Agents/pharmacology , Enzyme Inhibitors/pharmacology , Kanamycin Resistance/drug effects , Mycobacterium tuberculosis/drug effects , Acetyltransferases/antagonists & inhibitors , Acetyltransferases/chemistry , Antitubercular Agents/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Binding Sites , Enzyme Inhibitors/chemistry , Gene Expression Regulation, Bacterial/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Mycobacterium tuberculosis/growth & development , Protein Binding , Pyrazines/chemistry , Pyrazines/pharmacology , Structure-Activity Relationship
11.
ACS Med Chem Lett ; 7(12): 1219-1221, 2016 Dec 08.
Article in English | MEDLINE | ID: mdl-27994767

ABSTRACT

Drug-resistant tuberculosis (TB) is a global threat and innovative approaches such as using adjuvants of anti-TB therapeutics are required to combat it. High-throughput screening yielded two lead scaffolds of inhibitors of Mycobacterium tuberculosis (Mtb) acetyltransferase Eis, whose upregulation causes resistance to the anti-TB drug kanamycin (KAN). Chemical optimization on these scaffolds resulted in potent Eis inhibitors. One compound restored the activity of KAN in a KAN-resistant Mtb strain. Model structures of Eis-inhibitor complexes explain the structure-activity relationship.

12.
J Med Chem ; 59(23): 10619-10628, 2016 12 08.
Article in English | MEDLINE | ID: mdl-27933949

ABSTRACT

A two-drug combination therapy where one drug targets an offending cell and the other targets a resistance mechanism to the first drug is a time-tested, yet underexploited approach to combat or prevent drug resistance. By high-throughput screening, we identified a sulfonamide scaffold that served as a pharmacophore to generate inhibitors of Mycobacterium tuberculosis acetyltransferase Eis, whose upregulation causes resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN) in Mycobacterium tuberculosis. Rational systematic derivatization of this scaffold to maximize Eis inhibition and abolish the Eis-mediated KAN resistance of M. tuberculosis yielded several highly potent agents. A crystal structure of Eis in complex with one of the most potent inhibitors revealed that the inhibitor bound Eis in the AG-binding pocket held by a conformationally malleable region of Eis (residues 28-37) bearing key hydrophobic residues. These Eis inhibitors are promising leads for preclinical development of innovative AG combination therapies against resistant TB.


Subject(s)
Acetyltransferases/antagonists & inhibitors , Drug Resistance, Multiple, Bacterial/drug effects , Enzyme Inhibitors/pharmacology , Mycobacterium tuberculosis/drug effects , Sulfonamides/pharmacology , Acetyltransferases/metabolism , Anti-Bacterial Agents/pharmacology , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Humans , Kanamycin/pharmacology , Microbial Sensitivity Tests , Models, Molecular , Molecular Structure , Mycobacterium tuberculosis/metabolism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry
13.
ACS Chem Biol ; 11(6): 1639-46, 2016 06 17.
Article in English | MEDLINE | ID: mdl-27010218

ABSTRACT

A major cause of tuberculosis (TB) resistance to the aminoglycoside kanamycin (KAN) is the Mycobacterium tuberculosis (Mtb) acetyltransferase Eis. Upregulation of this enzyme is responsible for inactivation of KAN through acetylation of its amino groups. A 123 000-compound high-throughput screen (HTS) yielded several small-molecule Eis inhibitors that share an isothiazole S,S-dioxide heterocyclic core. These were investigated for their structure-activity relationships. Crystal structures of Eis in complex with two potent inhibitors show that these molecules are bound in the conformationally adaptable aminoglycoside binding site of the enzyme, thereby obstructing binding of KAN for acetylation. Importantly, we demonstrate that several Eis inhibitors, when used in combination with KAN against resistant Mtb, efficiently overcome KAN resistance. This approach paves the way toward development of novel combination therapies against aminoglycoside-resistant TB.


Subject(s)
Acetyltransferases/antagonists & inhibitors , Antitubercular Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Cyclic S-Oxides/pharmacology , Kanamycin Resistance/drug effects , Mycobacterium tuberculosis/drug effects , Thiazoles/pharmacology , Antitubercular Agents/chemistry , Crystallography, X-Ray , Cyclic S-Oxides/chemistry , Drug Design , High-Throughput Screening Assays , Kanamycin/metabolism , Kanamycin/pharmacology , Mycobacterium tuberculosis/enzymology , Staphylococcus aureus/drug effects , Structure-Activity Relationship , Thiazoles/chemistry
14.
PLoS One ; 11(2): e0147982, 2016.
Article in English | MEDLINE | ID: mdl-26840782

ABSTRACT

BACKGROUND: We combined hospital-based surveillance and health utilization survey data to estimate the incidence of respiratory viral infections associated hospitalization among children aged < 5 years in Bangladesh. METHODS: Surveillance physicians collected respiratory specimens from children aged <5 years hospitalized with respiratory illness and residing in the primary hospital catchment areas. We tested respiratory specimens for respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, influenza, adenovirus and rhinoviruses using rRT-PCR. During 2013, we conducted a health utilization survey in the primary catchment areas of the hospitals to determine the proportion of all hospitalizations for respiratory illness among children aged <5 years at the surveillance hospitals during the preceding 12 months. We estimated the respiratory virus-specific incidence of hospitalization by dividing the estimated number of hospitalized children with a laboratory confirmed infection with a respiratory virus by the population aged <5 years of the catchment areas and adjusted for the proportion of children who were hospitalized at the surveillance hospitals. RESULTS: We estimated that the annual incidence per 1000 children (95% CI) of all cause associated respiratory hospitalization was 11.5 (10-12). The incidences per 1000 children (95% CI) per year for respiratory syncytial virus, parainfluenza, adenovirus, human metapneumovirus and influenza infections were 3(2-3), 0.5(0.4-0.8), 0.4 (0.3-0.6), 0.4 (0.3-0.6), and 0.4 (0.3-0.6) respectively. The incidences per 1000 children (95%CI) of rhinovirus-associated infections among hospitalized children were 5 (3-7), 2 (1-3), 1 (0.6-2), and 3 (2-4) in 2010, 2011, 2012 and 2013, respectively. CONCLUSION: Our data suggest that respiratory viruses are associated with a substantial burden of hospitalization in children aged <5 years in Bangladesh.


Subject(s)
Hospitalization , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Age Factors , Bangladesh/epidemiology , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Patient Acceptance of Health Care , Public Health Surveillance
15.
Emerg Infect Dis ; 22(1): 24-31, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26691850

ABSTRACT

WU polyomavirus (WUPyV) was detected in a bone marrow transplant recipient with severe acute respiratory distress syndrome who died in 2001. Crystalline lattices of polyomavirus-like particles were observed in the patient's lung by electron microscopy. WUPyV was detected in the lung and other tissues by real-time quantitative PCR and identified in the lung and trachea by immunohistochemistry. A subset of WUPyV-positive cells in the lung had morphologic features of macrophages. Although the role of WUPyV as a human pathogen remains unclear, these results clearly demonstrate evidence for infection of respiratory tract tissues in this patient.


Subject(s)
Lung/virology , Polyomavirus Infections/diagnosis , Polyomavirus/isolation & purification , Respiratory Tract Infections/virology , Bone Marrow Transplantation , Child, Preschool , Female , Humans , Transplant Recipients
16.
Can J Microbiol ; 61(12): 938-47, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26492080

ABSTRACT

Despite the interactions known to occur between various lower respiratory tract pathogens and alveolar epithelial cells (AECs), few reports examine factors influencing the interplay between Mycobacterium tuberculosis bacilli and AECs during infection. Importantly, in vitro studies have demonstrated that the M. tuberculosis hbha and esxA gene products HBHA and ESAT6 directly or indirectly influence AEC survival. In this report, we identify Rv3351c as another M. tuberculosis gene that impacts the fate of both the pathogen and AEC host. Intracellular replication of an Rv3351c mutant in the human AEC type II pneumocyte cell line A549 was markedly reduced relative to the complemented mutant and parent strain. Deletion of Rv3351c diminished the release of lactate dehydrogenase and decreased uptake of trypan blue vital stain by host cells infected with M. tuberculosis bacilli, suggesting attenuated cytotoxic effects. Interestingly, an isogenic hbha mutant displayed reductions in AEC killing similar to those observed for the Rv3351c mutant. This opens the possibility that multiple M. tuberculosis gene products interact with AECs. We also observed that Rv3351c aids intracellular replication and survival of M. tuberculosis in macrophages. This places Rv3351c in the same standing as HBHA and ESAT6, which are important factors in AECs and macrophages. Defining the mechanism(s) by which Rv3351c functions to aid pathogen survival within the host may lead to new drug or vaccine targets.


Subject(s)
Bacterial Proteins/metabolism , Epithelial Cells/microbiology , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/metabolism , Pulmonary Alveoli/microbiology , Tuberculosis/microbiology , Bacterial Proteins/genetics , Cell Line , Cell Survival , Epithelial Cells/cytology , Humans , Macrophages/microbiology , Mycobacterium tuberculosis/genetics , Pulmonary Alveoli/cytology , Tuberculosis/physiopathology
18.
Antimicrob Agents Chemother ; 59(9): 5427-34, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26100699

ABSTRACT

The newer fluoroquinolones moxifloxacin (MXF) and levofloxacin (LVX) are becoming more common components of tuberculosis (TB) treatment regimens. However, the critical concentrations for testing susceptibility of Mycobacterium tuberculosis to MXF and LVX are not yet well established. Additionally, the degree of cross-resistance between ofloxacin (OFX) and these newer fluoroquinolones has not been thoroughly investigated. In this study, the MICs for MXF and LVX and susceptibility to the critical concentration of OFX were determined using the agar proportion method for 133 isolates of M. tuberculosis. Most isolates resistant to OFX had LVX MICs of >1 µg/ml and MXF MICs of >0.5 µg/ml. The presence of mutations within the gyrA quinolone resistance-determining regions (QRDR) correlated well with increased MICs, and the level of LVX and MXF resistance was dependent on the specific gyrA mutation present. Substitutions Ala90Val, Asp94Ala, and Asp94Tyr resulted in low-level MXF resistance (MICs were >0.5 but ≤2 µg/ml), while other mutations led to MXF MICs of >2 µg/ml. Based on these results, a critical concentration of 1 µg/ml is suggested for LVX and 0.5 µg/ml for MXF drug susceptibility testing by agar proportion with reflex testing for MXF at 2 µg/ml.


Subject(s)
Antitubercular Agents/pharmacology , Fluoroquinolones/pharmacology , Levofloxacin/pharmacology , Mycobacterium tuberculosis/drug effects , DNA Gyrase/genetics , Drug Resistance, Bacterial/genetics , Microbial Sensitivity Tests , Moxifloxacin , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/genetics
19.
J Antibiot (Tokyo) ; 68(3): 153-7, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25248725

ABSTRACT

Owing to the rise in drug resistance in tuberculosis combined with the global spread of its causative pathogen, Mycobacterium tuberculosis (Mtb), innovative anti mycobacterial agents are urgently needed. Recently, we developed a novel primase-pyrophosphatase assay and used it to discover inhibitors of an essential Mtb enzyme, primase DnaG (Mtb DnaG), a promising and unexplored potential target for novel antituberculosis chemotherapeutics. Doxorubicin, an anthracycline antibiotic used as an anticancer drug, was found to be a potent inhibitor of Mtb DnaG. In this study, we investigated both inhibition of Mtb DnaG and the inhibitory activity against in vitro growth of Mtb and M. smegmatis (Msm) by other anthracyclines, daunorubicin and idarubicin, as well as by less cytotoxic DNA intercalators: aloe-emodin, rhein and a mitoxantrone derivative. Generally, low-µM inhibition of Mtb DnaG by the anthracyclines was correlated with their low-µM minimum inhibitory concentrations. Aloe-emodin displayed threefold weaker potency than doxorubicin against Mtb DnaG and similar inhibition of Msm (but not Mtb) in the mid-µM range, whereas rhein (a close analog of aloe-emodin) and a di-glucosylated mitoxantrone derivative did not show significant inhibition of Mtb DnaG or antimycobacterial activity. Taken together, these observations strongly suggest that several clinically used anthracyclines and aloe-emodin target mycobacterial primase, setting the stage for a more extensive exploration of this enzyme as an antibacterial target.


Subject(s)
Antitubercular Agents/pharmacology , DNA Primase/antagonists & inhibitors , Intercalating Agents/pharmacology , Mycobacterium tuberculosis/drug effects , Microbial Sensitivity Tests , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/growth & development
20.
Antimicrob Agents Chemother ; 59(1): 444-9, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25385119

ABSTRACT

As the prevalence of multidrug-resistant and extensively drug-resistant tuberculosis strains continues to rise, so does the need to develop accurate and rapid molecular tests to complement time-consuming growth-based drug susceptibility testing. Performance of molecular methods relies on the association of specific mutations with phenotypic drug resistance and while considerable progress has been made for resistance detection of first-line antituberculosis drugs, rapid detection of resistance for second-line drugs lags behind. The rrs A1401G allele is considered a strong predictor of cross-resistance between the three second-line injectable drugs, capreomycin (CAP), kanamycin, and amikacin. However, discordance is often observed between the rrs A1401G mutation and CAP resistance, with up to 40% of rrs A1401G mutants being classified as CAP susceptible. We measured the MICs to CAP in 53 clinical isolates harboring the rrs A1401G mutation and found that the CAP MICs ranged from 8 µg/ml to 40 µg/ml. These results were drastically different from engineered A1401G mutants generated in isogenic Mycobacterium tuberculosis, which exclusively exhibited high-level CAP MICs of 40 µg/ml. These data support the results of prior studies, which suggest that the critical concentration of CAP (10 µg/ml) used to determine resistance by indirect agar proportion may be too high to detect all CAP-resistant strains and suggest that a larger percentage of resistant isolates could be identified by lowering the critical concentration. These data also suggest that differences in resistance levels among clinical isolates are possibly due to second site or compensatory mutations located elsewhere in the genome.


Subject(s)
Antibiotics, Antitubercular/therapeutic use , Capreomycin/therapeutic use , Microbial Sensitivity Tests/methods , Mycobacterium tuberculosis/drug effects , Tuberculosis, Multidrug-Resistant/genetics , Amikacin/therapeutic use , Drug Resistance, Multiple, Bacterial/genetics , Humans , Kanamycin/therapeutic use , Mutation , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...